Skip to Content

Notice

Controlled Substances: Proposed Revised Aggregate Production Quotas for 2000

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Drug Enforcement Administration (DEA), Justice.

ACTION:

Notice of proposed revised 2000 aggregate production quotas.

SUMMARY:

This notice proposes revised 2000 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

DATES:

Comments or objections must be received on or before August 18, 2000.

ADDRESSES:

Send comments or objectives to the Deputy Administrator, Drug Enforcement Administration, Washington, D.C. 20537, Attn.: DEA Federal Register Representative (CCR).

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 307-7183.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

On February 10, 2000, DEA published a notice of established initial 2000 aggregate production quotas for certain controlled substances in Schedules I and II (65 FR 6635). This notice stipulated that the Deputy Administrator of the DEA would adjust the quotas in early 2000 as provided for in Section 1303 of Title 21 of the Code of Federal Regulations.

The proposed revised 2000 aggregate production quotes represent those quantities of controlled substances in Schedules I and II that may be produced in the United States in 2000 to provide adequate supplies of each substance for: the estimated medical, scientific, research, and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

The proposed revisions are based on a review of 1999 year-end inventories, 1999 disposition data submitted by quota applicants, estimates of the medical needs of the United States, and other information available to the DEA.

In addition, in a final rule published in the Federal Register on March 13, 2000 (65 FR 13235) gamma-hydroxybutyric acid (GHB) and its salts, isomers, and salts of isomers was placed into Schedule I of the CSA. Applications for quota for this substance were submitted and the aggregate production quota for gamma-hydroxybutyric acid is proposed as listed below.

Therefore, under the authority vested in the Attorney General by Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Administrator hereby proposes the following revised 2000 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base:

Basic classPreviously established initial 2000 quotasProposed revised 2000 quotas
SCHEDULE I
2,5-Dimethoxyamphetamine10,001,00010,501,000
2,5-Dimethoxy-4-ethylamphetamine (DOET)22
3-Methylfentanyl1414
3-Methylthiofentanyl22
3,4-Methylenedioxyamphetamine (MDA)2020
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)3030
3,4-Methylenedioxymethamphetamine (MDMA)2020
3,4, 5-Trimethoxyamphetamine22
4-Bromo-2,5-Dimethoxyamphetamine (DOB)22
4-Bromo-2,5-Dimethoxyphenethylamine (2-CB)22
4-Methoxyamphetamine201,000201,000
4-Methylaminorex33
4-Methyl-2,5-Dimethoxyamphetamine (DOM)22
5-Methoxy-3,4-Methylenedioxyamphetamine22
Acetyl-alpha-methylfentanyl22
Acetyldihydrocodeine22
Acetylmethadol77
Allylprodine22
Alphacetylmethadol77
Alpha-ethyltryptamine22
Alphameprodine22
Alphamethadol22
Alpha-methylfentanyl22
Alpha-methylthiofentanyl22
Aminorex77
Benzylmorphine22
Betacetylmethadol22
Beta-hydroxy-3-methylfentanyl22 Start Printed Page 44837
Beta-hydroxyfentanyl22
Betameprodine22
Betamethadol22
Betaprodine22
Bufotenine22
Cathinone99
Codeine-N-oxide22
Diethyltryptamine22
Difenoxin10,00010,000
Dihydromorphine508,000508,000
Dimethyltryptamine33
Gamma-hydroxybutyric acid15,000,000
Heroin22
Hydroxypethidine22
Lysergic acid diethylamide (LSD)3863
Mescaline77
Methaqualone1717
Methcathinone99
Morphine-N-oxide22
N,N-Dimethylamphetamine77
N-Ethyl-1-Phenylcyclohexylamine (PCE)55
N-Ethylamphetamine77
N-Hydroxy-3,4-Methylenedioxyamphetamine22
Noracymethadol22
Norlevorphanol22
Normethadone77
Normorphine77
Para-fluorofentanyl22
Pholcodine22
Propiram415,000415,000
Psilocybin22
Psilocyn22
Tetrahydrocannabinols101,000115,000
Thiofentanyl22
Trimeperidine22
SCHEDULE II
1-Phenylcyclohexylamine1212
1-Piperidiocyclohexanecarbonitrile (PCC)1010
Alfentanil8,0008,000
Alphaprodine22
Amobarbital1212
Amphetamine9,007,0006,491,000
Cocaine251,000251,000
Codeine (for sale)54,504,00043,248,000
Codeine (for conversion)52,384,00052,384,000
Dextropropoxyphene114,078,000121,017,000
Dihydrocodeine268,000133,000
Diphenoxylate931,000931,000
Ecgonine36,00036,000
Ethylmorphine1212
Fentanyl300,000300,000
Glutethimide22
Hydrocodone (for sale)20,208,00021,417,000
Hydrocodone (for conversion)20,700,00020,700,000
Hydromorphone1,239,0001,239,000
Isomethadone1212
Levo-alphacetylmethadol (LAAM)201,00012
Levomethorphan22
Levorphanol27,00027,000
Meperidine11,335,0009,870,000
Metazocine11
Methadone (for sale)8,347,0008,347,000
Methadone (for conversion)600,0000
Methadone Intermediate9,503,0009,503,000
Methamphetamine2,049,0001,984,000
[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,225,000 grams for methamphetamine for conversion to a Schedule III product; and 9,000 grams for methamphetamine (for sale)]
Methylphenidate14,957,00014,957,000
Morphine (for sale)14,706,00014,706,000 Start Printed Page 44838
Morphine (for conversion)97,160,00097,410,000
Nabilone22
Noroxymorphone (for sale)25,00025,000
Noroxymorphone (for conversion)3,813,0003,813,000
Opium720,000720,000
Oxycodone (for sale)29,826,00032,575,000
Oxycodone (for conversion)271,0001,389,000
Oxymorphone166,000477,000
Pentobarbital22,037,00022,037,000
Phencyclidine4141
Phenmetrazine22
Phenylacetone1010
Secobarbital2222
Sufentanil1,7001,700
Thebaine41,300,00045,444,000

The Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero.

All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Administrator finds warrant a hearing, the Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing as per 21 CFR 1303.13(c) and 1303.32.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 13132, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage form manufacturers of Schedules I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Administrator has determined that this action does not require a regulatory flexibility analysis.

Start Signature

Dated: July 12, 2000.

Donnie R. Marshall,

Administrator.

End Signature End Supplemental Information

[FR Doc. 00-18148 Filed 7-18-00; 8:45 am]

BILLING CODE 4410-09-M